ValuEngine cut shares of Helius Medical Technologies (OTCMKTS:HSDT) from a hold rating to a sell rating in a report released on Friday morning.
Helius Medical Technologies (HSDT) opened at $2.23 on Friday. Helius Medical Technologies has a twelve month low of $1.29 and a twelve month high of $4.14.
In other news, Director Dane Andreeff purchased 167,000 shares of the stock in a transaction on Monday, November 13th. The stock was bought at an average price of $2.58 per share, for a total transaction of $430,860.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Blane Walter purchased 40,000 shares of the stock in a transaction on Friday, November 17th. The shares were purchased at an average price of $2.46 per share, with a total value of $98,400.00. The disclosure for this purchase can be found here. Insiders own 23.00% of the company’s stock.
Helius Medical Technologies Company Profile
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Helius Medical Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Helius Medical Technologies Inc. and related companies.